The JAK2 V617F mutation has been identified in ~50% of RARS-T patients and in only 2/89 cases of typical MDS, indicating that RARS-T should be considered as a JAK2 mutation-associated chronic MPN (3). Here, JAK2 is linked to myelodysplastic syndrome.